Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Implementation of the CYP Index for the Design of Selective Tryptophan-2,3-dioxygenase Inhibitors.
Parr BT, Pastor R, Sellers BD, Pei Z, Jaipuri FA, Castanedo GM, Gazzard L, Kumar S, Li X, Liu W, Mendonca R, Pavana RK, Potturi H, Shao C, Velvadapu V, Waldo JP, Wu G, Yuen PW, Zhang Z, Zhang Y, Harris SF, Oh AJ, DiPasquale A, Dement K, La H, Goon L, Gustafson A, VanderPorten EC, Mautino MR, Liu Y. Parr BT, et al. Among authors: mautino mr. ACS Med Chem Lett. 2020 Mar 4;11(4):541-549. doi: 10.1021/acsmedchemlett.0c00004. eCollection 2020 Apr 9. ACS Med Chem Lett. 2020. PMID: 32292562 Free PMC article.
Discovery of Clinical Candidate (1R,4r)-4-((R)-2-((S)-6-Fluoro-5H-imidazo[5,1-a]isoindol-5-yl)-1-hydroxyethyl)cyclohexan-1-ol (Navoximod), a Potent and Selective Inhibitor of Indoleamine 2,3-Dioxygenase 1.
Kumar S, Waldo JP, Jaipuri FA, Marcinowicz A, Van Allen C, Adams J, Kesharwani T, Zhang X, Metz R, Oh AJ, Harris SF, Mautino MR. Kumar S, et al. Among authors: mautino mr. J Med Chem. 2019 Jul 25;62(14):6705-6733. doi: 10.1021/acs.jmedchem.9b00662. Epub 2019 Jul 2. J Med Chem. 2019. PMID: 31264862
Discovery of indoximod prodrugs and characterization of clinical candidate NLG802.
Kumar S, Jaipuri FA, Waldo JP, Potturi H, Marcinowicz A, Adams J, Van Allen C, Zhuang H, Vahanian N, Link C Jr, Brincks EL, Mautino MR. Kumar S, et al. Among authors: mautino mr. Eur J Med Chem. 2020 Jul 15;198:112373. doi: 10.1016/j.ejmech.2020.112373. Epub 2020 May 1. Eur J Med Chem. 2020. PMID: 32422549 Free article.
Indoximod opposes the immunosuppressive effects mediated by IDO and TDO via modulation of AhR function and activation of mTORC1.
Brincks EL, Adams J, Wang L, Turner B, Marcinowicz A, Ke J, Essmann M, Mautino LM, Allen CV, Kumar S, Vahanian N, Link C, Mautino MR. Brincks EL, et al. Among authors: mautino mr. Oncotarget. 2020 Jun 23;11(25):2438-2461. doi: 10.18632/oncotarget.27646. eCollection 2020 Jun 23. Oncotarget. 2020. PMID: 32637034 Free PMC article.
Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors.
Nayak-Kapoor A, Hao Z, Sadek R, Dobbins R, Marshall L, Vahanian NN, Jay Ramsey W, Kennedy E, Mautino MR, Link CJ, Lin RS, Royer-Joo S, Liang X, Salphati L, Morrissey KM, Mahrus S, McCall B, Pirzkall A, Munn DH, Janik JE, Khleif SN. Nayak-Kapoor A, et al. Among authors: mautino mr. J Immunother Cancer. 2018 Jun 20;6(1):61. doi: 10.1186/s40425-018-0351-9. J Immunother Cancer. 2018. PMID: 29921320 Free PMC article. Clinical Trial.
A phase I study of indoximod in patients with advanced malignancies.
Soliman HH, Minton SE, Han HS, Ismail-Khan R, Neuger A, Khambati F, Noyes D, Lush R, Chiappori AA, Roberts JD, Link C, Vahanian NN, Mautino M, Streicher H, Sullivan DM, Antonia SJ. Soliman HH, et al. Oncotarget. 2016 Apr 19;7(16):22928-38. doi: 10.18632/oncotarget.8216. Oncotarget. 2016. PMID: 27008709 Free PMC article. Clinical Trial.
31 results